Elicio Therapeutics
ELTX
30 hedge funds and large institutions have $3.98M invested in Elicio Therapeutics in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 8 closing their positions.
0.68% less ownership
Funds ownership: 17% → 16.31% (-0.68%)
15% less capital invested
Capital invested by funds: $4.71M → $3.98M (-$723K)
21% less funds holding
Funds holding: 38 → 30 (-8)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$120K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.44K |
| 3 |
BlackRock
New York
|
+$1.08K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.03K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$618 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$79.3K |
| 2 |
Millennium Management
New York
|
-$45.7K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$29.9K |
| 4 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$24.3K |
| 5 |
E
Ergoteles
New York
|
-$23.6K |
ELTX Hedge Fund Activity: Q4 2022 in Review
30 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q4 2022, worth a combined $3.98M — down 15% from $4.71M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ELTX and 0 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was CM Management, adding an estimated $120K. The largest seller was Renaissance Technologies, cutting an estimated $79.3K.
- 30 institutional investors held Elicio Therapeutics (ELTX) as of Q4 2022, down from 38 in Q3 2022.
- Funds reported $3.98M of Elicio Therapeutics stock for Q4 2022, down 15% quarter-over-quarter.
- 0 funds opened new Elicio Therapeutics positions in Q4 2022 and 8 closed out, a net change of -8 holders.
- The largest Elicio Therapeutics buyer in Q4 2022 was CM Management, an estimated $120K added.
- The largest Elicio Therapeutics seller in Q4 2022 was Renaissance Technologies, an estimated $79.3K sold.
Based on aggregated 13F filings for Q4 2022.